The vytorin on carotid intima-media thickness and overall arterial rigidity (VYCTOR) study

Journal of Clinical Pharmacology

Volumn 49, Issue 7, 2009, Pages 838-847

  Meaney, Alejandra ^a,c   Ceballos, Guillermo ^b   Asbun, Juan ^b   Solache, Gustavo ^a   Mendoza, Emma ^a   Vela, Agustín ^a   Meaney, Eduardo ^a,b  

^a CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c Delegación Gustavo A Madero ^*  (Mexico)

Author keywords

Atherosclerosis; Cardiovascular risk; Ezetimibe; Inflammation; Intima media thickness reduction; LDL cholesterol; PCR; Statins

Indexed keywords

C REACTIVE PROTEIN; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNAL CAROTID ARTERY; MALE; MYALGIA; RANDOMIZED CONTROLLED TRIAL; RASH; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CAROTID ARTERY, INTERNAL; CHOLESTEROL; CORONARY DISEASE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SIMVASTATIN; TRIGLYCERIDES; TUNICA INTIMA; TUNICA MEDIA;

EID: 67650475384     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270009337011     Document Type: Article

References (68)

1. Sánchez-Castillo CP, Velázquez-Monroy O., Lara-Esqueda A., et al. Diabetes and hypertension increases in a society with abdominal obesity: results of the Mexican National Health Survey 2000. Public Health Nutr. 2004 ; 8: 53-60.
2. Frenk J., Bobadilla JL, Sepúlveda J., López M. Health transition in middle-income countries: new challenges for the organization of services. Health Policy Plan. 1989 ; 4: 29-39. (Pubitemid 19085715)
3. Rivera JA, Barquera S., Campirano F., Campos I., Safdie M., Tovar V. Epidemiological and nutritional transition in México: rapid increase of non-communicable chronic diseases and obesity. Public Health Nutr. 2002 ; 5 (1A). 113-122. (Pubitemid 41128297)
4. Olaiz G., Rojas R., Barquera S., et al. Encuesta Nacional de Salud y Nutrición 2006. Cuernavaca, México: Instituto Nacional de Salud Pública ; 2006.
5. Meaney E., Lara-Esqueda A., Ceballos-Reyes GM, et al. Cardiovascular risk factors in the urban Mexican population: the FRIMEX study. Public Health. 2007 ; 121: 378-384. (Pubitemid 46485274)
6. Mortalidad 2000-2005. Sistema nacional de Información. http://sinais.salud.gob.mx/mortalidad. Accessed April 23, 2008.
7. Nesto RW Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs. 2005 ; 5: 379-387. (Pubitemid 41584838)
8. Aguilar-Salinas CA, Olaiz G., Valles V., et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001 ; 42: 1298-1307. (Pubitemid 32744254)
9. Ciruzzi M., Schargrodsky H., Pramparo P., et al. Attributable risks for acute myocardial infarction in four countries of Latin America. Medicina (B Aires). 2003 ; 63: 697-703. (Pubitemid 38054769)
10. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497.
11. Pavía López AA, Gaxiola S., Violante R., Gómez Àlvarez E., Rodríguez Gilabert C. Tratamien to farmacológico. In: Pavía López AA, Velázquez Monroy O, eds. Primer Consenso Mexicano para el Diagnóstico y Tratamiento de las Dislipidemias. México, D.F.: Intersistemas, S. A. de C.V. ; 2005: 135-147.
12. Alberts AW HMG-CoA reductase inhibitors: the development. Atheroscler Rev. 1988 ; 18: 123-131.
13. Shepherd J., Cobbe SM, Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995 ; 333: 1301-1307.
14. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet. 1994 ; 334: 1384-1389.
15. Downs JR, Clearfield M., Weis S., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998 ; 279: 1615-1622. (Pubitemid 28248586)
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 ; 360: 7-22.
17. Riegger G., Abletshauser C., Ludwig M., et al. The effect of fluvastin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 1999 ; 144: 263-270. (Pubitemid 29259987)
18. Nissen SE, Tuzcu EM, Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 ; 291: 1071-1080. (Pubitemid 38541684)
19. Nissen SE, Nicholls SJ, Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID Trial. JAMA. 2006 ; 295: 1556-1565.
20. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110: 227-239. (Pubitemid 38924592)
21. Pearson TA, Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000 ; 160: 459-467. (Pubitemid 30112269)
22. Meaney E., Vela A., Ramos A., Alemao E., Yin D. Cumplimiento de las metas con reductores del cholesterol en pacientes mexicanos. El Estudio COMETA México. Gac Med Mex. 2004 ; 140: 493-501. (Pubitemid 39485220)
23. Bourgault C., Davignon J., Fodor G., et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study-Observational (CALIPSO). Can J Cardiol. 2005 ; 21: 1187-1193. (Pubitemid 43013529)
24. Euroaspire I. and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries: European Action on Secondary Prevention by Intervention to Reduce Events. Lancet. 2001 ; 357: 995-1001.
25. van Heek M., Farley C., Compton D., Hoos L., Davis H. The novel cholesterol absorption inhibitor, ezetimibe, selectively inhibits the intestinal absorption of free cholesterol in the presence and absence of exocrine pancreatic function [abstract]. Atherosclerosis. 2000 ; 151: 155.
26. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002 ; 90: 1092-1097. (Pubitemid 35335597)
27. Gagne C., Bays HE, Weiss SR, et al. Ezetimibe Study Group, INCONNU. Am J Cardiol. 2002 ; 90: 1084-1091.
28. Stein S., Stender P., Mata P., et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004 ; 148: 447-455. (Pubitemid 39265117)
29. Ballantyne CM, Abate N., Yuan Z., King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 2005 ; 149: 464-473. (Pubitemid 40585409)
30. Kastelein JJP, Akdim F., Stroes ESG, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008 ; 358: 1431-1443.
31. Howard BV, Roman MJ, Devereux RB, et al. Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA. 2008 ; 299: 1678-1689.
32. Amarenco P., Labreuche J., Lavallée P., Touboul P-J. Statins in stroke prevention and carotid atherosclerosis. Stroke. 2004 ; 35: 2902-2909.
33. World Medical Association, Declaration of Helsinki. http://ohsr.od.nih. gov/helsinki.php3
34. ICH Guidelines for Good Clinical Practice. International Conference on Harmonisation for Technical Requirements for the Registration of Pharmaceuticals for Human Use. London: ICH ; 1996.
35. Ley General de Salud, Reglamento de Investigación Clínica. Título 5-°. Capítulo único. Diario oficial de la Federación. December 24, 1986.
36. Friedwald WT, Levy IR, Frederickson DS Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18: 499-502.
37. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999 ; 340: 14-22. (Pubitemid 29024679)
38. Iglesias del Sol A., Bots ML, Grobbee DE, Hofman A., Witteman JCM. Carotid intima-media thickness at different sites: relation to incident myocardial infarction. The Rotterdam Study. Eur Heart J. 2002 ; 23: 934-940. (Pubitemid 35203871)
39. Meaney E., Samaniego V., Soletero E., González, Moguer R, Vela A. Vascular dynamics in isolated systolic arterial hypertension. Clin Cardiol. 1995 ; 18: 721-725. (Pubitemid 26034666)
40. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results: I. Reduction in incidence of coronary heart disease. JAMA. 1984 ; 251: 351-364.
41. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986 ; 8: 1245-1255. (Pubitemid 17208898)
42. Cobbe SM How best to combat the enemies? Lipid lowering. Eur Heart J Suppl. 2002 ; 4: A48 - A52.
43. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004 ; 109: 11139-11143.
44. Liao KJ, Laufs U. Pleitropic effects of statins. Ann Rev Pharmacol Toxicol. 2005 ; 45: 89-118.
45. Zhang FL, Casey PJ Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996 ; 65: 241-269. (Pubitemid 26250610)
46. Fuster V., Badimon L., Badimon J., Chesebro JH The pathogenesis of coronary artery disease and the acute coronary syndromes: part I. N Engl J Med. 1992 ; 326: 242-250.
47. Fuster V., Badimon L., Badimon J., Chesebro JH The pathogenesis of coronary artery disease and the acute coronary syndromes: part II. N Engl J Med. 1992 ; 326: 310-318.
48. Sacks F., Pfeffer M., Moye L., et al, for the CARE investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996 ; 335: 1001-1009. (Pubitemid 26338729)
49. Neal CR, Jones PH Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manag. 2006 ; 2: 31-38.
50. Daskalopoulou SS, Mikhaidilis DP Ezetimibe/simvastatin single tablet versus rosuvastatin in patients with hypercholesterolemia. Curr Med Res Op. 2006 ; 22: 2037-2039. (Pubitemid 44663408)
51. Espeland MA, O'Leary DH, Ferry JG, Morgan T., Evans G., Mudra H. Carotid intima-media thickness as a surrogate for cardiovascular disease events in trial of HGM-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med. 2005 ; 6: 3.
52. Simon A., Gariepy J., Chironi G., Megnien JL, Levenson J. Intima-media thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens. 2002 ; 20: 159-169. (Pubitemid 34913777)
53. McMurry MP, Connor WE, Lin DS, Cerqueira MT, Connor SL The absorption of cholesterol and the sterol balance in the Tarahumara Indians of Mexico fed cholesterol-free and high cholesterol diets. Am J Clin Nutr. 1985 ; 41: 1289-1298. (Pubitemid 15031374)
54. Sudhop T., L-1/4tjohann D., Kodal A., et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002 ; 106: 1943-1948. (Pubitemid 35176299)
55. Altmann SW, Davis HR Jr, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004 ; 303: 1201-1204. (Pubitemid 38233587)
56. Castañeda-Hernández G., Hoyo-Vadillo C., Palma-Aguirre JA, Flores-Murrieta FJ Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol. 1993 ; 33: 140-145. (Pubitemid 23089636)
57. Castañeda-Hernández G., Palma-Aguirre JA, Montoya-Cabrera MA, Flores-Murrieta FJ Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol. 1996 ; 41: 433-434. (Pubitemid 26145027)
58. Chávez-Teyes L., Castañeda-Hernández G., Flores-Murrieta FJ Pharmacokinetics of midazolam in Mexicans: evidence for interethnic variability. Clin Drug Invest. 1999 ; 17: 233-239. (Pubitemid 29145737)
59. Flores-Murrieta FJ, Castañeda-Hernández G., Granados-Soto V., Herrera JE Increased bioavailability of sildenafil in Mexican men. JAMA. 2000 ; 283: 1825-1826. (Pubitemid 30207615)
60. Carrasco-Portugal MC, Aguilar-Carrasco JC, Luján M., Reyes-García G., Medina-Santillán R., Flores-Murrieta FJ Further evidence for interethnic differences in the oral pharmacokinetics of meloxicam. Clin Drug Invest. 2005 ; 25: 307-313. (Pubitemid 40806944)
61. Taylor AJ, Kent SM, Flaherty PJ, Coyle LC, Markwood TT, Vernalis MN ARBITER: arterial biology for the investigation of the treatment effects of reducing cholesterol. A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima media thickness. Circulation. 2002 ; 106: 2055-2060. (Pubitemid 35192810)
62. Stein EA After ENHANCE-is more LDL cholesterol lowering still better ? Clin Chem. 2008 ; 54: 940-942. (Pubitemid 351793398)
63. Orio F. Jr, Palomba S., Cascella T., et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab. 2005 ; 90: 6072-6076. (Pubitemid 41606527)
64. Meaney E., Vela A., Samaniego V., et al. Metformin, arterial function, intima-media thickness, and nitroxidation in the metabolic syndrome. Clin Exp Pharmacol Physiol. 2008 ; 35: 895-903. (Pubitemid 351951937)
65. Koenig W., Sund M., Frölich M., et al. C-reactive protein, a sensitive marker of inflammation, predicts future risks of coronary heart disease in initially middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999 ; 99: 237-242. (Pubitemid 29056365)
66. Di Napoli M., Schwaninger M., Cappelli R., et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke. 2005 ; 36: 1316-1329. (Pubitemid 40798763)
67. Chapman CML, Beilby JP, Maquillan BM, Thompson PL, Hung J. Monocyte count, but not C-reactive protein or interleukin-6, is an independent risk marker for subclinical carotid atherosclerosis. Stroke. 2004 ; 35: 1619-1624. (Pubitemid 38823636)
68. Danesh J., Pepys MB C-reactive protein in healthy and in sick populations. Eur Heart J. 2000 ; 21: 1564-1556.